QuidelOrtho (QDEL) Cash from Financing Activities (2021 - 2026)
QuidelOrtho (QDEL) reported Cash from Financing Activities of $37.6 million for Q1 2026, up 113.64% on a YoY basis from $17.6 million in Q1 2025, and up 438.74% sequentially from -$11.1 million in Q4 2025.
QuidelOrtho (QDEL) Cash from Financing Activities (2021 - 2026) Analysis & Trends
QuidelOrtho (QDEL) has 6 years of Cash from Financing Activities data on file, last reported at $37.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities rose 113.64% year-over-year to $37.6 million; the trailing twelve-month figure through Mar 2026 stood at $175.8 million (up 107.07% YoY), and the FY2025 full-year result was $155.8 million, up 219.26% from the prior year.
- Cash from Financing Activities grew to $37.6 million in Q1 2026, from -$11.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $424.2 million in Q1 2023 to a low of -$99.7 million in Q3 2023.
- A 5-year average of $26.5 million and a median of -$11.1 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities plunged 1652.94% in 2023 and jumped 274.9% in 2025, its largest moves.
- Tracing QDEL's Cash from Financing Activities over 5 years: stood at -$3.4 million in 2022, then slumped by 1600.0% to -$57.8 million in 2023, then fell by 19.2% to -$68.9 million in 2024, then jumped by 83.89% to -$11.1 million in 2025, then surged by 438.74% to $37.6 million in 2026.
- Business Quant data shows QDEL's Cash from Financing Activities at $37.6 million in Q1 2026, -$11.1 million in Q4 2025, and $46.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.03 Bn | 175.74 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 129.38 Bn | 126.50 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 108.86 Bn | 99.64 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 68.57 Bn | 67.12 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 28.64 Bn | 27.52 Bn | 750.30 Mn | -25.00 Mn |
| 7 | GE HealthCare Technologies | 28.55 Bn | 26.27 Bn | 1.98 Bn | 21.00 Mn |
| 8 | Smith & Nephew | 27.02 Bn | 26.44 Bn | - | - |
| 9 | Koninklijke Philips | 25.54 Bn | 22.42 Bn | 2.07 Bn | -26.93 Mn |
| 10 | QuidelOrtho | 1.15 Bn | 1.01 Bn | - | 37.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 37.60 Mn |
| Mar 29, 2026 | 37.60 Mn |
| Dec 28, 2025 | -11.10 Mn |
| Dec 28, 2025 | -11.10 Mn |
| Sep 28, 2025 | 46.00 Mn |
| Sep 28, 2025 | 46.00 Mn |
| Jun 29, 2025 | 103.30 Mn |
| Jun 29, 2025 | 103.30 Mn |
| Mar 30, 2025 | 17.60 Mn |
| Mar 30, 2025 | 17.60 Mn |
| Dec 29, 2024 | -68.90 Mn |
| Dec 29, 2024 | -68.90 Mn |
| Sep 29, 2024 | -26.30 Mn |
| Sep 29, 2024 | -26.30 Mn |
| Jun 30, 2024 | 162.50 Mn |
| Jun 30, 2024 | 162.50 Mn |
| Mar 31, 2024 | -18.50 Mn |
| Mar 31, 2024 | -18.50 Mn |
| Dec 31, 2023 | -57.80 Mn |
| Dec 31, 2023 | -57.80 Mn |